Strategy Therapy on Cancer Therapy-Related Cardiac Dysfunction
Chemotherapeutic Toxicity, Cardiotoxicity, Heart Failure
About this trial
This is an interventional prevention trial for Chemotherapeutic Toxicity
Eligibility Criteria
Inclusion Criteria: Patients who are newly diagnosed with breast cancer or lymphoma and never accepted anti-cancer therapy Age 20-65 years old Systolic blood pressure ≥ 110 mmHg Exclusion Criteria: End-stage renal disease (estimated Glomerulus Filtration Rate <15 mL/min/1.73 m2) Echocardiography Baseline left ventricle ejection fraction < 50% Allergy history to angiotensin receptor blockers Life expectancy < 1 year Pregnancy Unwilling to participate in this clinical study
Sites / Locations
- National Cheng Kung University HospitalRecruiting
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm 4
Experimental
No Intervention
No Intervention
Experimental
Prevention therapy
Conventional therapy
Global longitudinal strain (GLS) function decreased >15%, No intervention
GLS function descending >15%, Rescue therapy
Sacubitril/Valsartan (25/80) mg twice a day for 1 year
No intervention
With the value of GLS function via echocardiography study decreased >15%, No intervention
Sacubitril/Valsartan (25/80) mg twice a day for 1 year